Back to News
Market Impact: 0.35
AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised Guidance
Source: zacks.com
Corporate EarningsCorporate Guidance & OutlookCompany FundamentalsHealthcare & Biotech
Amgen shares fell despite Q3 earnings and revenue beats. Steep declines in Prolia and Xgeva offset growth across key drug portfolios, while the company raised its 2026 guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment
AMGN0.10
More News
- UBS raises Amgen stock price target to $530 on diversification
- Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
- Truist raises Amgen stock price target on earnings beat
- Reed Jobs’s Yosemite raises $350 million second fund to make cancer non-lethal
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- A blue wave sends futures into the green